THU0254 Residual Inflammatory Activity Assessed by A Multi-Biomarker Disease Activity Blood Test is Linked to Structural Damage in RA Patients in Low Disease Activity/Remission and Normal C-Reactive Protein Level

Background The autoantibody positive (AAB+) subset of rheumatoid arthritis (RA) patients is prone to develop bone damage. Since the extent of bone erosion in AAB+ RA shows substantial variation, we hypothesized that, next to AAB, the level of local and systemic inflammation and tissue metabolism is the second factor determining damage. We therefore evaluated inflammation with a multi-biomarker disease activity (MBDA) blood test that measures serum concentrations of 12 inflammatory mediators related to local tissue metabolism and systemic acute phase response. Objectives Determine the relationship between disease activity in patients with RA, assessed by a MBDA score, and the volume and number of bone erosions, assessed with micro-computed tomography (micro-CT). Methods 78 AAB+ RA patients in remission or low disease activity (DAS28